Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphocyte ultrastructure in patients with multiple sclerosis

R Djaldetti1, A Achiron, I Ziv

  • 1Department of Neurology, Beilinson Medical Center, Petah-Tiqva, Israel.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is the walk ratio a window to the cerebellum in multiple sclerosis? A structural magnetic resonance imaging study.

European journal of neurology·2019
Same author

Neural correlates of gait variability in people with multiple sclerosis with fall history.

European journal of neurology·2018
Same author

Retinal layers thickness changes following epiretinal membrane surgery.

Eye (London, England)·2017
Same author

Experimental Autoimmune Encephalomyelitis Ameliorated by Passive Transfer of Polymerase 1-Silenced MOG35-55 Lymphatic Node Cells: Verification of a Novel Therapeutic Approach in Multiple Sclerosis.

Neuromolecular medicine·2017
Same author

Psoriasis comorbidity affects multiple sclerosis neurological progression: a retrospective case - control analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis.

Journal of neuroimmunology·2016

Lymphocytes in relapsing-remitting multiple sclerosis (RRMS) show distinct ultrastructural changes, particularly in mitochondria. Intravenous immunoglobulin treatment normalized these lymphocyte alterations, suggesting they reflect disease-related activation.

Area of Science:

  • Immunology
  • Neuroscience
  • Cell Biology

Background:

  • Relapsing-remitting multiple sclerosis (RRMS) is an autoimmune disease affecting the central nervous system.
  • Lymphocyte alterations are implicated in MS pathogenesis.
  • Intravenous immunoglobulin (IVIg) is a therapeutic option for MS.

Purpose of the Study:

  • To investigate the ultrastructural differences in lymphocytes between untreated RRMS patients, IVIg-treated MS patients, and healthy controls.
  • To determine if observed lymphocyte ultrastructural changes in RRMS are reversible with IVIg therapy.

Main Methods:

  • Electron microscopy was used to analyze the ultrastructure of peripheral blood lymphocytes.
  • Lymphocytes from RRMS patients, IVIg-treated MS patients, and healthy volunteers were compared.

Related Experiment Videos

  • Quantitative analysis of lymphocyte mitochondria (number and size) was performed.

    • Main Results:

    • Untreated RRMS patients exhibited significant differences in lymphocyte ultrastructure compared to healthy controls.
    • Key differences included alterations in the number and size of mitochondria within lymphocytes.
    • These ultrastructural abnormalities largely resolved following 12 months of IVIg treatment.

    Conclusions:

    • The observed lymphocyte ultrastructural changes in RRMS are likely indicative of lymphocyte activation.
    • IVIg treatment appears to modulate or reverse these disease-specific lymphocyte alterations.
    • These findings contribute to understanding the role of lymphocytes in MS pathogenesis and the mechanism of IVIg therapy.